{"title":"验证COBAS®AmpliPrep/COBAS®TaqMan HIV-1测试v2.0的性能,用于HIV-1血浆病毒载量的量化。","authors":"Ella Christelle Brou, Aboubakar Touré, Fidèle Sounan Touré, Eugénie Yaudé, Inza Dosso, Marcellin Konan, Durand Sery, Christiane Kiki-Barro","doi":"10.1684/abc.2025.1972","DOIUrl":null,"url":null,"abstract":"<p><p>The laboratory of the National Institute of Public health makes HIV-1 plasma RNA quantification. That test is required to follow up HIV patient on ART (Antiretroviral therapy). The laboratory was accredited by the West African Accreditation System (SOAC) in 2022 for HIV real time PCR. Here we report the experience of the laboratory for verifiying performance of the COBAS® AmpliPrep/COBAS® TaqMan (CAP/CTM) HIV-1 test, v 2.0 kit for measuring viral load by real time PCR. According with the technical guides of the French Accreditation Committee (COFRAC) and the recommendations of the French Society of Clinical Biology (SFBC), different steps were followed. These are the risk assessment, the study of reliability, intermediate precision, accuracy and precision of the method, estimation of measurement uncertainty and comparison of methods. Coefficient of variation for repeatability, reproducibility and trueness were within target of 5 %. The results from the CAP/CTM were reproductible and identical to those of the COBAS 6800. The COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Test, v 2.0 method is suitable for routine laboratory use and has analytical performance for its intended utility, which mean the assessment of disease progression and monitoring of antiretroviral therapy for HIV-1 patients.</p>","PeriodicalId":93870,"journal":{"name":"Annales de biologie clinique","volume":"83 3","pages":"310-320"},"PeriodicalIF":0.4000,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Vérification des performances de la méthode COBAS® AmpliPrep/COBAS® TaqMan HIV-1 test, v 2.0 pour la quantification de la charge virale plasmatique du VIH-1.\",\"authors\":\"Ella Christelle Brou, Aboubakar Touré, Fidèle Sounan Touré, Eugénie Yaudé, Inza Dosso, Marcellin Konan, Durand Sery, Christiane Kiki-Barro\",\"doi\":\"10.1684/abc.2025.1972\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The laboratory of the National Institute of Public health makes HIV-1 plasma RNA quantification. That test is required to follow up HIV patient on ART (Antiretroviral therapy). The laboratory was accredited by the West African Accreditation System (SOAC) in 2022 for HIV real time PCR. Here we report the experience of the laboratory for verifiying performance of the COBAS® AmpliPrep/COBAS® TaqMan (CAP/CTM) HIV-1 test, v 2.0 kit for measuring viral load by real time PCR. According with the technical guides of the French Accreditation Committee (COFRAC) and the recommendations of the French Society of Clinical Biology (SFBC), different steps were followed. These are the risk assessment, the study of reliability, intermediate precision, accuracy and precision of the method, estimation of measurement uncertainty and comparison of methods. Coefficient of variation for repeatability, reproducibility and trueness were within target of 5 %. The results from the CAP/CTM were reproductible and identical to those of the COBAS 6800. The COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Test, v 2.0 method is suitable for routine laboratory use and has analytical performance for its intended utility, which mean the assessment of disease progression and monitoring of antiretroviral therapy for HIV-1 patients.</p>\",\"PeriodicalId\":93870,\"journal\":{\"name\":\"Annales de biologie clinique\",\"volume\":\"83 3\",\"pages\":\"310-320\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2025-06-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales de biologie clinique\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1684/abc.2025.1972\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales de biologie clinique","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1684/abc.2025.1972","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
国家公共卫生研究所的实验室使HIV-1血浆RNA定量。这项测试是跟踪艾滋病毒患者抗逆转录病毒治疗的必要条件。该实验室于2022年获得西非认可系统(SOAC)对艾滋病毒实时PCR的认可。在这里,我们报告了实验室验证COBAS®AmpliPrep/COBAS®TaqMan (CAP/CTM) HIV-1检测试剂盒的性能的经验,该试剂盒用于通过实时PCR测量病毒载量。根据法国认证委员会(COFRAC)的技术指南和法国临床生物学学会(SFBC)的建议,采取了不同的步骤。这些是风险评估,可靠性研究,中间精密度,准确度和精密度的方法,测量不确定度的估计和方法的比较。重复性、再现性、准确度的变异系数均在5%的目标范围内。CAP/CTM的结果是可重复的,并且与COBAS 6800的结果相同。COBAS®AmpliPrep/COBAS®TaqMan HIV-1 Test, v 2.0方法适用于常规实验室使用,并具有其预期效用的分析性能,这意味着评估HIV-1患者的疾病进展和监测抗逆转录病毒治疗。
Vérification des performances de la méthode COBAS® AmpliPrep/COBAS® TaqMan HIV-1 test, v 2.0 pour la quantification de la charge virale plasmatique du VIH-1.
The laboratory of the National Institute of Public health makes HIV-1 plasma RNA quantification. That test is required to follow up HIV patient on ART (Antiretroviral therapy). The laboratory was accredited by the West African Accreditation System (SOAC) in 2022 for HIV real time PCR. Here we report the experience of the laboratory for verifiying performance of the COBAS® AmpliPrep/COBAS® TaqMan (CAP/CTM) HIV-1 test, v 2.0 kit for measuring viral load by real time PCR. According with the technical guides of the French Accreditation Committee (COFRAC) and the recommendations of the French Society of Clinical Biology (SFBC), different steps were followed. These are the risk assessment, the study of reliability, intermediate precision, accuracy and precision of the method, estimation of measurement uncertainty and comparison of methods. Coefficient of variation for repeatability, reproducibility and trueness were within target of 5 %. The results from the CAP/CTM were reproductible and identical to those of the COBAS 6800. The COBAS® AmpliPrep/COBAS® TaqMan HIV-1 Test, v 2.0 method is suitable for routine laboratory use and has analytical performance for its intended utility, which mean the assessment of disease progression and monitoring of antiretroviral therapy for HIV-1 patients.